A new electronic artificial urinary sphincter lets men restore bladder control at the push of a key-fob button — a potential upgrade over devices that require an awkward manual squeeze. Early results are promising, but the study is tiny.
Beyond A, B and O lies a hidden world of rare blood types. Researchers have finally pinned down the genetic source of one that eluded science since 1972 — a discovery that could save the lives of a tiny, hard-to-match group of patients.
With psychedelic therapies advancing toward the market, a public FDA hearing wrestled with a central tension: how to protect patients without building an approval system so restrictive that few can actually use them.
Thousands of clinical trials recruit at any moment, yet most eligible patients never join — and it’s usually not because they refuse. The bigger failure is an information system that buries the trials they’d qualify for.
Bundibugyo virus, a lesser-known cousin of Ebola, has caused its largest outbreak on record in Central Africa — and there’s no licensed vaccine or treatment for it.
In a 12-week pilot, people with early Huntington’s who confined eating to a daily window showed improvements in disease and nerve-damage markers — but with no control group, the researchers stress it’s far from proof.
Interim results from a randomized trial suggest that halving the length of antibiotic treatment for surgically treated orthopedic infections doesn’t worsen outcomes — and causes fewer side effects.
IUD placement can hurt — and patients have long said so. A double-blind randomized trial found a lidocaine paracervical block reduced pain, especially for those who’ve never given birth.
Brenipatide belongs to the same class as tirzepatide — but it’s tuned for the brain. Early data have Lilly moving it straight into late-stage trials for alcohol use disorder and depression.
The faith’s governing body will now permit members to accept the major blood components and blood-derived products, while maintaining its prohibition on whole-blood transfusions.
Ultragenyx priced Fayuvi, its just-approved gene therapy for a fatal childhood disease, at $3.95 million — reigniting the hard question of how society pays for one-time treatments that carry blockbuster price tags but treat only a handful of patients.
Removing the fallopian tubes during another planned surgery can sharply cut the risk of the deadliest ovarian cancer. The evidence is strong; the challenge is making sure eligible people are actually offered it.